-
公开(公告)号：US20240076355A1
公开(公告)日：2024-03-07
申请号：US18259695
申请日：2022-01-14
申请人： ASKGENE PHARMA, INC.
发明人： Yuefeng LU
IPC分类号： C07K14/715 , A61K47/68 , A61P35/00 , C07K16/24 , C07K16/28
CPC分类号： C07K14/7156 , A61K47/6813 , A61K47/6845 , A61K47/6849 , A61K47/6889 , A61P35/00 , C07K16/249 , C07K16/2827
摘要： Provided herein are interferon prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.
-
公开(公告)号：US20210163562A1
公开(公告)日：2021-06-03
申请号：US17262940
申请日：2019-07-25
申请人： ASKGENE PHARMA, INC.
发明人： Yuefeng LU , Chunxiao YU
IPC分类号： C07K14/54 , C07K14/715 , C07K16/28 , A61P35/00
摘要： Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.
-
公开(公告)号：US20230303714A1
公开(公告)日：2023-09-28
申请号：US17991775
申请日：2022-11-21
发明人： Yuefeng Lu , Kurt Shanebeck , Lu Li , Lei Liu , Shiwen Zhang , Lan Yang , Jian-Feng Lu
IPC分类号： C07K16/30 , A61P35/00 , A61K47/68 , C07K14/765 , C07K14/55 , C07K14/54 , C07K16/28 , A61K31/282 , A61K31/337 , A61K39/395
CPC分类号： C07K16/3046 , A61P35/00 , A61K47/6863 , C07K14/765 , C07K14/55 , C07K14/5443 , C07K16/2809 , A61K31/282 , A61K31/337 , A61K39/39558 , C07K2317/31 , C07K2317/565 , C07K2317/24 , C07K2317/732 , C07K2317/734 , A61K2039/505
摘要： Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.
-
公开(公告)号：US20170327569A1
公开(公告)日：2017-11-16
申请号：US15593280
申请日：2017-05-11
发明人： Yuefeng Lu , Jian-Feng Lu
IPC分类号： C07K16/22 , C07K14/71 , C07K14/515 , A61K39/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K14/515 , C07K14/71 , C07K2317/14 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/32 , C07K2319/70
摘要： The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.
-
公开(公告)号：US20160083444A1
公开(公告)日：2016-03-24
申请号：US14857799
申请日：2015-09-17
申请人： AskGene Pharma, Inc.
发明人： Jian-Feng Lu , Yuefeng Lu , Aijun Wang , Donggou He , Kurt Shanebeck , Chen Yao
IPC分类号： C07K14/505 , C07K16/00
CPC分类号： C07K14/505 , A61K38/00 , C07K2319/30
摘要： The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.
摘要翻译： 本说明书公开了促红细胞生成素受体激动剂，包含这种促红细胞生成素受体激动剂的组合物和药物，用于促红细胞生成素受体激动剂及其组合物和药物的方法和用途，以及促红细胞生成素受体激动剂和用于治疗贫血的组合物和药物的方法和用途。
-
公开(公告)号：US20240076331A1
公开(公告)日：2024-03-07
申请号：US18259706
申请日：2022-02-01
申请人： ASKGENE PHARMA, INC.
发明人： Yuefeng LU
IPC分类号： C07K14/495 , C07K14/54
CPC分类号： C07K14/495 , C07K14/5428 , A61K38/00 , C07K2319/50
摘要： The present disclosure relates to prodrugs or chimeric molecules which comprise a carrier moiety, a cytokine moiety selected from an IL-10 agonist polypeptide and a TGF-β agonist polypeptide, and a masking moiety that binds to said cytokine moiety and inhibits its biological activity. Further included in the present disclosure are methods of making and using the novel prodrugs or chimeric molecules.
-
公开(公告)号：US20220289822A1
公开(公告)日：2022-09-15
申请号：US17635683
申请日：2020-08-21
申请人： ASKGENE PHARMA, INC.
IPC分类号： C07K14/705 , C07K14/54 , C07K14/55 , C07K14/715 , C07K16/24 , A61P35/00
摘要： Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.
-
公开(公告)号：US20210260163A1
公开(公告)日：2021-08-26
申请号：US16979404
申请日：2019-03-11
申请人： ASKGENE PHARMA, INC.
发明人： Chunxiao YU , Yuefeng LU , Jian-Feng LU
摘要： Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.
-
公开(公告)号：US11059885B2
公开(公告)日：2021-07-13
申请号：US16380852
申请日：2019-04-10
申请人： AskGene Pharma Inc.
发明人： Yuefeng Lu , Jian-Feng Lu
IPC分类号： C07K16/22 , A61K9/08 , A61K9/19 , C07K14/71 , C07K14/515
摘要： The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
-
公开(公告)号：US20190106494A1
公开(公告)日：2019-04-11
申请号：US16111158
申请日：2018-08-23
发明人： Aijun Wang , Kurt Shanebeck , Donggou He , Chen Yao , Lu Li , Fang Xia , Yuefeng Lu , Jian-Feng Lu , Lan Yang
摘要： The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.015 秒)
